Effect of Simvastatin on Cardiac Function

Sponsor
Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT01178710
Collaborator
(none)
151
1
2
22
6.9

Study Details

Study Description

Brief Summary

It is well know that statins have been used to low cholesterol to prevent and treat coronary artery disease for many years. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. However, some results were controversial. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators are trying to see whether statins can protect heart injury during cardiac surgery in Chinese. Part of patients will receive statin treatment and part of will not before surgery in the study. Both patients' heart function will be measured and compared after surgery to determine whether statins can protect heart injury during heart surgery.

Detailed Description

Cardiac function is crucial for cardiac surgery. The mortality remains very high in patients with poor cardiac function preoperation, long surgical time, complicate or difficult surgical procedure or uncompleted corrected malformation currently. Thus, it is necessary to search other approaches to improve cardiac function for cardiac surgery patients in order to increase the success, decrease complication and mortality in cardiac surgery.

Although statin has been used to low cholesterol to prevent and treat coronary artery disease for many years, it has been reported that statin could protect endothelial function and cardiac function in coronary artery bypass graft. However, some results were controversy. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalence.Thus, it is necessary to perform a double blind, randomised clinical trial in China to determine whether statin can protect heart injury during heart surgery in China and what's its mechanism.

Study Design

Study Type:
Interventional
Actual Enrollment :
151 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial
Study Start Date :
Sep 1, 2010
Actual Primary Completion Date :
Jun 1, 2011
Actual Study Completion Date :
Jul 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: treatment

Drug: Simvastatin
20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Other Names:
  • simcor
  • No Intervention: untreated

    control

    Outcome Measures

    Primary Outcome Measures

    1. plasma troponin T level [within the first 7 days after surgery]

      The investigator will measure the plasma troponin T level in several time points before and after surgery in each patient.

    Secondary Outcome Measures

    1. the index of B ultrasound on heart [one year after surgery]

      Each patient will be followed up and checked with B ultrasound on heart in 1,3,6 and 12 months after surgery. The index of B ultrasound on heart, such as ejection fraction, the diameter of left ventricle, will be measured

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • cyanotic congenital heart disease

    • noncyanotic congenital heart disease with pulmonary hypertension

    • Heart valve disease,

    • other heart and great artery diseases need heart or great artery surgery

    Exclusion Criteria:
    • Coronary artery disease

    • under 10-year-old.

    • noncyanotic congenital heart disease without pulmonary hypertension

    • poor liver function such AST elevated,Hepatitis

    • Gestation women and Breast-feeding women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The First Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong China 510080

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    • Principal Investigator: Jing-song Ou, MD,PhD, The Frist Affiliated Hospital, Sun Yat-sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Jing-song Ou, associate chief, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT01178710
    Other Study ID Numbers:
    • statinstudy1
    First Posted:
    Aug 10, 2010
    Last Update Posted:
    Jul 26, 2012
    Last Verified:
    Jul 1, 2012

    Study Results

    No Results Posted as of Jul 26, 2012